1. Boiko SS, Korotkov SA, Zherdev VP, Gudasheva TA, Ostrovskaya RU. Pharmacokinetics of a new potential dipeptide nootropic drug GVS-111 and its metabolites in the rat brain. Khim.-Farm. Zh. 2001;35(9):11-13. Russian.
2. Zherdev VP, Boyko SS, Shevchenko RV, Bochkov PO, Gribakina OV, Raskin SYu. The role of studies of interspecies differences pharmacokinetics in the creation of new peptide drugs. Eksp. Klin. Farmakol. 2004;67(1):40-43. doi: https://doi.org/10.30906/0869-2092-2004-67-1-40-43.Russian.
3. Gudasheva TA, Kolyasnikova KN, Kuznetsova EA, Litvinova SA, Zolotov NN, Voronina TA, Ostrovskaya RU, Seredenin SB. N-phenylacetyl-glycyl-L-proline ethyl ester converts into cyclo-L-prolyl-glycine showing a similar spectrum of neuropsychotropic activity. Khim.-Farm. Zh. 2016;50(11):3-8. Russian.
4. Seredenin SB, Gudasheva TA, Kolyasnikova KN, Kuznetsova EA, Voronina TA, Yarkova MA, Antipova TA, Litvinova SA, Zolotov NN. Patent RU No. 2646604. Novel glyprolins with nootropic, anti-hypoxic, neuroprotective and anssiylitis activity. Bull. No. 7. Published March 6, 2018.
5. Diao L, Meibohm B. Pharmacokinetics and pharmacokineticpharmacodynamic correlations of therapeutic peptides. Clin. Pharmacokinet. 2013;52(10):855-868. doi: https://doi.org/10.1007/s40262-013-0079-0